Deciphering Cholesterol's Role in PD-L2 Stability: A Distinct Regulatory Mechanism From PD-L1

被引:0
作者
Zhang, Yu [1 ,2 ]
Xiao, Taoran [1 ,2 ]
Wen, Maorong [1 ]
Shen, Lijuan [1 ]
Du, Lingyu [1 ]
Wei, Shukun [1 ]
Wu, Bin [3 ]
Yu, Yang [3 ]
Wang, Shuqing [1 ,2 ,4 ]
Ouyang, Bo [1 ,2 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Ctr Excellence Mol Cell Sci, State Key Lab Mol Biol, 320Yueyang Rd, Shanghai 200031, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
[3] Chinese Acad Sci, Shanghai Adv Res Inst, ZhangJiang Lab, Natl Facil Prot Sci Shanghai, Shanghai 201203, Peoples R China
[4] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therapeu, Qixiangtai Rd 22, Tianjin 300070, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
PD-L2; PD-L1; NMR spectroscopy; cholesterol binding motif; protein stability; PROTEIN; EXPRESSION; DYNAMICS; CELLS;
D O I
10.1016/j.jmb.2024.168500
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Programmed cell death 1 ligand 2 (PD-L2), a member of the B7 immune checkpoint protein family, emerges as a crucial player in immune modulation. Despite its functional overlap with programmed cell death 1 ligand 1 (PD-L1) in binding to the programmed cell death protein 1 (PD-1) on T cells, PD-L2 exhibits a divergent expression pattern and a higher affinity for PD-1. However, the regulatory mechanisms of PD-L2 remain under-explored. Here, our investigations illustrate the pivotal role of cholesterol in modulating PD-L2 stability. Using advanced nuclear magnetic resonance (NMR) and biochemical analyses, we demonstrate a direct and specific binding between cholesterol and PD-L2, mediated by an F-xxx-V-xxLR motif in its transmembrane domain, distinct from that in PD-L1. This interaction stabilizes PD-L2 and prevents its downstream degradation. Disruption of this binding motif compromises PD-L20s cellular stability, underscoring its potential significance in cancer biology. These findings not only deepen our understanding of PD-L2 regulation in the context of tumors, but also open avenues for potential therapeutic interventions. (c) 2024 Elsevier Ltd. All rights reserved.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation
    Fan, Zhiwei
    Wu, Changyue
    Chen, Miaomiao
    Jiang, Yongying
    Wu, Yuanyuan
    Mao, Renfang
    Fan, Yihui
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (03) : 1041 - 1053
  • [22] Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
    Krueger, Kimberly
    Mayer, Zsuzsanna
    Kottmaier, Marc
    Gerckens, Miriam
    Boeck, Stefan
    Luppa, Peter
    Holdenrieder, Stefan
    BIOMEDICINES, 2022, 10 (10)
  • [23] Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
    Liu, Jingwei
    Li, Hao
    Sun, Liping
    Yuan, Yuan
    Xing, Chengzhong
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [24] Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry
    Kwiecien, Iwona
    Rutkowska, Elzbieta
    Polubiec-Kownacka, Malgorzata
    Raniszewska, Agata
    Rzepecki, Piotr
    Domagala-Kulawik, Joanna
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (04) : 1679 - 1689
  • [25] PD-1, CTLA4, PD-L1 and PD-L2 DNA methylation in papillary thyroid carcinoma
    de Vos, Luka
    Dietrich, Joern
    Strieth, Sebastian
    Bootz, Friedrich
    Dietrich, Dimo
    Franzen, Alina
    IMMUNOTHERAPY, 2020, 12 (12) : 903 - 920
  • [26] Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses
    Liang, SC
    Latchman, YE
    Buhlmann, JE
    Tomczak, MF
    Horwitz, BH
    Freeman, GJ
    Sharpe, AH
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (10) : 2706 - 2716
  • [27] Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
    Garcia-Diaz, Angel
    Shin, Daniel Sanghoon
    Moreno, Blanca Homet
    Saco, Justin
    Escuin-Ordinas, Helena
    Rodriguez, Gabriel Abril
    Zaretsky, Jesse M.
    Sun, Lu
    Hugo, Willy
    Wang, Xiaoyan
    Parisi, Giulia
    Saus, Cristina Puig
    Torrejon, Davis Y.
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Hu-Lieskovan, Siwen
    Damoiseaux, Robert
    Lo, Roger S.
    Ribas, Antoni
    CELL REPORTS, 2017, 19 (06): : 1189 - 1201
  • [28] PD-L1/PD-L2 genetic profile in the molecular cytogenetic classification of classic Hodgkin lymphoma
    Garcia-Montenegro, Mauro
    Narbaitz, Marina
    Metrebian, Maria Fernanda
    Pavlovsky, Astrid
    Slavutsky, Irma
    VIRCHOWS ARCHIV, 2025, : 1039 - 1047
  • [29] PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis
    Carter, Laura L.
    Leach, Michael W.
    Azoitei, Mihai L.
    Cui, Junqing
    Pelker, Jeffrey W.
    Jussif, Jason
    Benoit, Steve
    Ireland, Gretchen
    Luxenberg, Deborah
    Askew, G. Roger
    Milarski, Kim L.
    Groves, Christopher
    Brown, Tom
    Carito, Brenda A.
    Percival, Karen
    Carreno, Beatriz M.
    Collins, Mary
    Marusic, Suzana
    JOURNAL OF NEUROIMMUNOLOGY, 2007, 182 (1-2) : 124 - 134
  • [30] AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer
    Spirina, L. V.
    Avgustinovich, A. V.
    Afanas'ev, S. G.
    Kondakova, I. V.
    Volkov, M. Yu.
    Dobrodeev, A. Yu.
    Boronkina, A. I.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 170 (01) : 75 - 78